209 related articles for article (PubMed ID: 28925066)
1. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Cheng HH; Abida W; Ellis L; Harshman LC; Spratt DE; Simons JW; Pienta KJ; Soule HR
Prostate; 2017 Nov; 77(15):1478-1488. PubMed ID: 28925066
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Den RB; Carlo MI; de Leeuw R; Hope TA; Karzai F; McKay RR; Salami SS; Simons JW; Pienta KJ; Soule HR
Prostate; 2019 Feb; 79(3):244-258. PubMed ID: 30381857
[TBL] [Abstract][Full Text] [Related]
3. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Roychowdhury S; Goswami S; Ippolito JE; Priceman SJ; Pritchard CC; Sfanos KS; Subudhi SK; Simons JW; Pienta KJ; Soule HR
Prostate; 2017 Feb; 77(2):123-144. PubMed ID: 27679977
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Sharp A; Ellis L; Jones J; Kaochar S; Larman HB; Quigley DA; Ye H; Simons JW; Pienta KJ; Soule HR
Prostate; 2020 Feb; 80(2):113-132. PubMed ID: 31825540
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
Miyahira AK; Zarif JC; Coombs CC; Flavell RR; Russo JW; Zaidi S; Zhao D; Zhao SG; Pienta KJ; Soule HR
Prostate; 2022 Feb; 82(2):169-181. PubMed ID: 34734426
[TBL] [Abstract][Full Text] [Related]
6. Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting.
Miyahira AK; Hawley JE; Adelaiye-Ogala R; Calais J; Nappi L; Parikh R; Seibert TM; Wasmuth EV; Wei XX; Pienta KJ; Soule HR
Prostate; 2023 Feb; 83(3):207-226. PubMed ID: 36443902
[TBL] [Abstract][Full Text] [Related]
7. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
[TBL] [Abstract][Full Text] [Related]
8. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.
Miyahira AK; Lang JM; Den RB; Garraway IP; Lotan TL; Ross AE; Stoyanova T; Cho SY; Simons JW; Pienta KJ; Soule HR
Prostate; 2016 Feb; 76(2):125-39. PubMed ID: 26477609
[TBL] [Abstract][Full Text] [Related]
10. The 22nd annual prostate cancer foundation scientific retreat report.
Miyahira AK; Simons JW; Soule HR
Prostate; 2016 Sep; 76(12):1037-52. PubMed ID: 27272144
[TBL] [Abstract][Full Text] [Related]
11. Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting.
Pienta KJ; Walia G; Simons JW; Soule HR
Prostate; 2014 Feb; 74(3):314-20. PubMed ID: 24249419
[TBL] [Abstract][Full Text] [Related]
12. The 24th Annual Prostate Cancer Foundation scientific retreat report.
Miyahira AK; Soule HR
Prostate; 2018 Sep; 78(12):867-878. PubMed ID: 29761524
[TBL] [Abstract][Full Text] [Related]
13. The 26th Annual Prostate Cancer Foundation Scientific Retreat Report.
Miyahira AK; Soule HR
Prostate; 2021 Jan; 81(1):3-19. PubMed ID: 33085787
[TBL] [Abstract][Full Text] [Related]
14. The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
Miyahira AK; Soule HR
Prostate; 2022 Oct; 82(14):1346-1377. PubMed ID: 35852016
[TBL] [Abstract][Full Text] [Related]
15. The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
Miyahira AK; Soule HR
Prostate; 2021 Nov; 81(15):1107-1124. PubMed ID: 34469608
[TBL] [Abstract][Full Text] [Related]
16. The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
Miyahira AK; Soule HR
Prostate; 2017 Jul; 77(10):1093-1106. PubMed ID: 28503903
[TBL] [Abstract][Full Text] [Related]
17. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
Pant MK; Abughaban A; Aragon-Ching JB
Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
20. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
